Clinical Trials
429
53 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1890
Active, not recruiting
25
5.8%
Completed
218
50.8%
Enrolling By Invitation
4
0.9%
No Longer Available
1
0.2%
Not yet recruiting
24
5.6%
Recruiting
73
17.0%
Suspended
1
0.2%
Terminated
46
10.7%
Unknown
2
0.5%
Withdrawn
35
8.2%
No approval data available
- The University of Oklahoma Health Campus convened its first AI Symposium to map how artificial intelligence can improve care, research and education across the state. - OU leaders cited Oklahoma's ranking of 49th in many health outcomes, with high rates of diabetes, cancer, cardiovascular and behavioral health conditions, as motivation for AI-driven innovation. - Clinical AI is already deployed for triaging medical images, clinician documentation, patient risk prediction and estimating hospital readmission likelihood, with clinicians retaining oversight. - Officials set a five-year horizon to move key health indicators and emphasized building data infrastructure, governance and AI literacy into physician training.
- University of Oklahoma researchers discovered that triple-negative breast cancer recruits macrophages to release BDNF, a protein that attracts nerves into tumors to fuel growth. - Blocking BDNF signaling with an existing drug significantly reduced nerve infiltration and tumor growth in mouse models. - Analysis of patient data showed that higher levels of macrophages and BDNF in tumors were associated with poorer survival outcomes. - The findings point to a potential new treatment strategy targeting macrophage-nerve communication rather than cancer cells directly, with plans to expand testing to ovarian cancer.
- The University of Oklahoma has been awarded an $11.5 million NIH Phase I grant to establish the Oklahoma Center of ImmunoEngineering, a five-year initiative to accelerate immune-based disease research. - The center will house two specialized cores: the Immunomodulation Technology Core for experimental work and the Omics Data Science Core for computational analysis, AI, and predictive modeling. - Four early-career faculty will lead research projects spanning coronavirus infection in bats, glioblastoma immunotherapy, peptide-based cancer vaccines, and alveolar soft part sarcoma. - The center aims to build research capacity in Oklahoma, a state historically receiving lower levels of federal research funding through the NIH Institutional Development Award program.
- University of Oklahoma researchers published breakthrough findings in Science Signaling revealing new understanding of how amylin receptors function, providing crucial insights for obesity drug development. - The study developed novel biochemical and pharmacological methods to analyze how drugs interact with each of the three distinct amylin receptors that control appetite and blood sugar. - Researchers discovered that amylin receptors share core components but have unique accessory subunits, and that drugs can either pull these subunits together or push them apart. - The findings provide pharmaceutical companies with previously unavailable tools to understand exactly how their amylin-based obesity drugs affect each receptor type.
- University of Oklahoma researchers developed Smart-T, a real-time adaptive smartphone app that nearly doubled smoking cessation rates compared to a static app in a clinical trial of 454 low-income smokers. - The app uses an algorithm to assess smoking risk throughout the day and delivers personalized interventions based on users' stress levels, mood, and environmental factors. - Smart-T users showed significantly higher engagement, found the app more helpful, and were more likely to request additional nicotine replacement therapy during the six-month study period. - The trial represents one of the first mobile health studies to biochemically verify smoking status using breath carbon monoxide measurements and facial recognition technology.
- International researchers launch NANORAY-312 trial investigating hafnium metal therapy combined with radiation as a novel treatment approach for head and neck cancer patients unsuitable for cisplatin treatment. - Recent Lancet study reveals durvalumab immunotherapy failed to outperform cetuximab when combined with radiation therapy, highlighting the ongoing challenge in finding alternatives to cisplatin. - University of Oklahoma joins 160 global sites in testing innovative hafnium-based approach designed to enhance radiation effectiveness while preserving healthy tissue.
